Dry Eye Syndromes Clinical Trial
Official title:
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
EYEdeal Scanning Technology enables rapid measurement of corneal and scleral topography. By accurately measuring the ocular surface with this imaging technology, the current iterative fitting method required to fit PROSE (prosthetic replacement of the ocular surface ecosystem) devices could be replaced and/or strengthened with a more rapid, automated fitting sequence. This could considerably reduce the time needed per visit, the number of visits, and the number of devices needed to be manufactured to reach the endpoint. Additionally, the scanning technology may afford the opportunity to successfully fit some pathology that were previously treatment failures. The automated technology may as well reduce the intensive clinician training time needed to fit PROSE devices, therefore increasing the availability and access to patients. The goal of this research is to evaluate the reliability and efficacy of this automated technology for fitting PROSE devices. Data from real-time measurement of the human eye ocular surface topography will be used to fabricate a prosthetic lens. The fit of the PROSE device will be evaluated, as well as the subjective comfort of the fit.
Inclusion and Exclusion Criteria The participant will be eligible to participate if the following criteria apply: 1. Written Informed Consent has been obtained prior to any study-related procedures 2. Male or female, 18 years of age and older prior to the initial visit 3. Established wearer of PROSE in the study eye with an optimized fit in the opinion of the clinician 4. No medical need for a PROSE retreatment or replacement lens at the time of enrollment in the study eye, in the opinion of the clinician 5. Initial PROSE fitting was initiated and completed at BostonSight, Needham 6. Current PROSE device does not have channels or fenestrations 7. Currently wears a PROSE device in the study eye primarily for an irregular ocular surface /irregular cornea (including but not limited to Keratoconus, Pellucid Marginal Degeneration, Ectasia, Post-Penetrating Keratoplasty, Corneal Scar, Trauma) AND/OR ocular surface disease 8. Has the ability to NOT wear the current PROSE device in the study eye for 3 days prior to scan and 3 days prior to first fitting appointment in the opinion of the investigator and subject 9. In the opinion of the investigator, the subject has the ability to follow study instructions 10. In the opinion of the investigator, the subject has the ability to complete all study procedures and visits The participant would NOT be eligible to participate if at least one of the following criteria is met: 1. Is currently participating in any other type of eye-related clinical or research study 2. Is pregnant or nursing as reported by the subject 3. Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study 4. Has had previous ocular surgery within the past 12 weeks 5. Intolerance to PROSE wear 6. Inability to maintain stable fixation and exposure for ocular surface imaging 7. Corneal touch by the posterior surface of the device in current PROSE device 8. Allergy to sodium fluorescein 9. Patient is an employee of BostonSight 10. Subject is currently incarcerated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
| Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
| Recruiting |
NCT04701086 -
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
|
N/A | |
| Active, not recruiting |
NCT03697876 -
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
|
Phase 1 | |
| Terminated |
NCT02815293 -
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
|
Phase 3 | |
| Completed |
NCT02910713 -
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
|
N/A | |
| Completed |
NCT04104997 -
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
|
Phase 1 | |
| Recruiting |
NCT02595606 -
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
|
Phase 4 | |
| Completed |
NCT01711424 -
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
|
N/A | |
| Completed |
NCT01202747 -
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
|
Phase 2/Phase 3 | |
| Completed |
NCT01015209 -
Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
|
Phase 1 | |
| Completed |
NCT00969280 -
Acupuncture for Dry Eye Syndrome
|
Phase 3 | |
| Completed |
NCT00756678 -
Efficacy and Acceptability of Two Lubricant Eye Drops
|
Phase 4 | |
| Completed |
NCT01496482 -
Comparison of Evaporimetry With the Established Methods of Tear Film Measurement
|
N/A | |
| Completed |
NCT00739713 -
Effects of Sea Buckthorn Oil on Dry Eye
|
N/A | |
| Completed |
NCT00370747 -
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
|
Phase 2 | |
| Completed |
NCT00349440 -
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
|
Phase 4 | |
| Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
| Completed |
NCT02871440 -
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
|
Phase 3 | |
| Completed |
NCT05042960 -
Computer Screen Properties Study
|
N/A |